Tirzepatide is a once-weekly injectable medication originally developed to treat type 2 diabetes. It’s now widely used under medical supervision for weight management, as it helps control blood sugar and significantly reduces appetite by acting on two key hormone pathways (GLP-1 and GIP).

As of November 2023, the FDA approved Zepbound (brand name for Tirzepatide) specifically for chronic weight management in adults with obesity (BMI ≥30) or those who are overweight (BMI ≥27) with a related condition such as high blood pressure, type 2 diabetes, or high cholesterol.

Tirzepatide targets two hormones that regulate hunger and digestion:

GLP-1: Helps you feel full faster and longer

GIP: Enhances insulin sensitivity and may further reduce appetite

Together, they support significant weight reduction, especially when combined with a healthy diet and lifestyle.

We offer Tirzepatide via telehealth, meaning you’ll consult with our licensed provider virtually. After approval, your medication is shipped directly to your door. It’s self-administered once per week, and we’ll guide you through every step of the process with instructions and follow-up support.

Common side effects can include nausea, constipation, diarrhea, or decreased appetite, especially in the first few weeks. Most side effects are temporary and manageable. Rare but serious risks include pancreatitis or thyroid issues—our team will review your health history thoroughly before prescribing.